Immunotherapy combination effective for patients with high-grade neuroendocrine cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Many patients with rare, fast-growing neuroendocrine tumors respond well to a combination of ipilimumab and nivolumab, according to the first peer-reviewed publication out of DART, a rare cancer clinical trial.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login